AR and posterior cortical atrophy: For histologically progressed non-metastatic PCa that is castration sensitive, a multimodal treatment design entailing ADT with or without RP and/or RT or combined with an AR inhibitor offers the greatest potential for improved long-term outcomes for patients who may harbor occult metastatic disease [9,10].